- OPEN ACCESS REVIEW
- Delaying Emergence of Resistance to KRAS Inhibitors with Adaptive Therapy: “Treatment-to-Contain” Instead of “Treatment-to-Cure”
- Oncologie, Vol.24, No.2, pp. 185-194, 2022, DOI:10.32604/oncologie.2022.023629
- Abstract KRAS mutations are among the most common oncogenic abnormalities in cancer. Until recently, drug discovery pursuing KRAS did not produce therapeutic benefits for patients. Specific KRAS inhibitors, such as sotorasib and adagrasib, which bind covalently to codon 12 of substituted glycine to cysteine residue of the protein (G12C), have been approved by the FDA recently for the treatment of lung cancers. Binding of these drugs to the protein inhibits the activation of the GDP-bound inactive state to the GTP-bound active state. Phase 1/2 trials have shown potential anti-tumor activity, particularly in patients with previously treated non-small cell lung cancer. Acquired… More
-
Views:192
Downloads:163
Download PDF
- OPEN ACCESS ARTICLE
- The Transcriptional and Immunological Roles of Six2 in Clear Cell Renal Cell Carcinoma
- Oncologie, Vol.24, No.2, pp. 261-282, 2022, DOI:10.32604/oncologie.2022.022838
- Abstract Background: Six2, a transcription factor, exerts an oncogenic role in clear cell renal cell carcinoma (ccRCC). Increased Six2 expression could enhance cancer metastasis. However, the regulatory mechanism of Six2 in promoting metastasis remains unclear. The purpose of this study is to analyze the regulatory pattern of Six2 and the potential role of Six2 in the tumor immune microenvironment. Materials and Methods: Firstly, transcriptional data in TCGA-KIRC cohorts was used to analyze the relationship between Six2 expression and clinical information. Secondly, we detect the association between Six2 and the tumor immune microenvironment in ccRCC. Then, we analyzed Six2-related differentially expressed genes… More
-
Views:171
Downloads:138
Download PDF
- OPEN ACCESS REVIEW
- Use of the Naphthoquinone YM155 (Sepantronium Bromide) in the Treatment of Cancer: A Systematic Review and Meta-Synthesis
- Oncologie, Vol.24, No.2, pp. 195-225, 2022, DOI:10.32604/oncologie.2022.022299
- Abstract Most cancer cells overexpress the anti-apoptotic protein survivin and display redox dysregulation originating from genotypic and phenotypic alterations. These disturbances contribute to the uncontrolled proliferation, invasion, and chemoresistance of cancer cells, yet they also represent a specific vulnerability that could be exploited therapeutically in selected tumors. YM155 (sepantronium bromide) is a naphthoquinone-containing imidazolebased compound that selectively inhibits survivin expression at the transcriptional and post-transcriptional levels. Here, we performed a systematic review and meta-analysis of clinical studies in which YM155 was administered as monotherapy or combination therapy for patients with cancer. We assessed fully or partially reported clinical outcomes and pharmacological… More
-
Views:317
Downloads:139
Download PDF
- OPEN ACCESS ARTICLE
- Development and Validation of a Nomogram Model to Predict the Prognosis of Intrahepatic Cholangiocarcinoma
- Oncologie, Vol.24, No.2, pp. 329-340, 2022, DOI:10.32604/oncologie.2022.022521
- Abstract Background: The effective method for predicting prognosis of ICC is still lack. This study aims to establish and verify an effective prognostic nomogram model for intrahepatic cholangiocarcinoma (ICC) after partial hepatectomy. Materials and Methods: A nomogram model was developed in a cohort of 127 patients from January 2015 to December 2019. General clinical characteristics including preoperative physical examination data and postoperative pathological features were obtained. The independent risk factors identified by univariate and multivariate COX proportional hazards regression models were used to construct nomogram model. Predictive accuracy and discriminative ability were determined using a concordance index and a calibration curve.… More
-
Views:258
Downloads:126
Download PDF
- OPEN ACCESS CASE REPORT
- Surgery Combined with Molecular Targeted Therapy Successfully Treated Giant Esophageal Gastrointestinal Stromal Tumor
- Oncologie, Vol.24, No.2, pp. 349-356, 2022, DOI:10.32604/oncologie.2022.022436
- Abstract Gastrointestinal stromal tumors (GISTs) are rare neoplasms arising from mesenchymal cells of the digestive tract and abdomen. Only a few isolated cases of giant esophageal GISTs (greater than 5 cm in size) have been reported with clinical features and surgical methods. Radical esophagectomy with negative margins, followed by gastric tube reconstruction, is recommended for giant esophageal GISTs. However, patients undergoing this type of surgery experienced a sharp decrease in food intake (due to the removal of most of the stomach) and were prone to eating regurgitation, resulting in poor quality of life. We describe the case of a 65-year-old man… More
-
Views:255
Downloads:128
Download PDF
- OPEN ACCESS ARTICLE
- Chinese Herbal Prescription QYSL Prevents Progression of Lung Cancer by Targeting Tumor Microenvironment
- Oncologie, Vol.24, No.2, pp. 295-307, 2022, DOI:10.32604/oncologie.2022.022116
- Abstract Objectives: Lung cancer is a common and malignant tumor in adults and ranks first in the incidence and mortality of the top five malignant tumors in China. Our previous studies have shown that QYSL prescription can balance lung cancer mice Th1/Th2 and inhibit tumor cell immune escape. Here, we examined the effects of QYSL on lung cancer associated macrophage and the potential associated mechanism. Methods: C57BL/6 mice were injected with Lewis lung cancer cells and treated with QYSL. FACS, RT-PCR, and western blot were used to examined the effect of QYSL on tumor immune microenvironment. Results: We found QYSL inhibited… More
-
Views:267
Downloads:124
Download PDF
Cited by: